Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 29;7(1):100028.
doi: 10.1016/j.jve.2021.100028. eCollection 2021 Mar.

The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV

Laura Waters  1 , Viraj Mehta  2 , Jaideep Gogtay  2 , Marta Boffito  3   4
Affiliations
Review

The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV

Laura Waters et al. J Virus Erad. .

Abstract

This article evaluates the evidence supporting use of the tenofovir disoproxil fumarate (TDF) plus lamivudine (3 ​TC) combination as a dual nucleoside backbone within a triple drug antiretroviral regimen. Key trials that assess the relative efficacy, safety and resistance profile of 3 ​TC and emtricitabine (FTC) are discussed. Clinical use of 3 ​TC and FTC with two tenofovir prodrugs -TDF and tenofovir alafenamide (TAF) - is presented. Recommendations from various international guidelines for the construction of triple and emerging dual regimens are summarised. In conclusion, data suggest the therapeutic equivalence of 3 ​TC and FTC, especially when 3 ​TC is combined with TDF.

Keywords: Antiretroviral therapy; Lamivudine; NRTI backbone; Tenofovir.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Global HIV and AIDS statistics – 2019 fact sheet. 2020. https://www.unaids.org/en/resources/fact-sheet Last Available at: accessed February 19.
    1. Piot P., Quinn T.C. Response to the AIDS pandemic – a global health model. NEJM. 2013;368:2210–2218. - PMC - PubMed
    1. Trogarzo S.P.C. 2020. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSea... Available at: Last accessed February 19.
    1. Clercq E.D. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009;33:307–320. - PubMed
    1. Caplan M.R., Daar E.S., Corado K.C. Next generation fixed dose combination pharmacotherapies for treating HIV. Expet Opin Pharmacother. 2018;19(6):589–596. - PubMed

LinkOut - more resources